PASG: Passage Bio Corp Analyst Consensus Forecast
Biomedical production facilities are operating steadily as they undergo an equipment upgrade for centrifugation. However, global tensions and sanctions are hindering biomaterial logistics and the execution of overseas tests. This price chart, with a value of 15.53, reflects the price action of Passage Bio, Inc. (PASG), a developer of gene therapies for children whose profits are based on exclusive rights to orphan drugs.
Analytical breakdowns for Passage Bio, Inc. (PASG)
- share price and expert price forecast:
- market capitalization information:
- balance sheet equity data:
- issuer credit burden and liquidity indicators:
Debt to Equity Ratio Passage Bio, Inc.|PASG - Long-Term Debt to Capital|Current Liabilities to Capital passagebio.com|PASG - Company Total Debt|Debts to Book Capitalization Passage Bio Corp|PASG - Company Long-Term Debt|Company Short-Term Loans and Borrowings Passage Bio|Immediate Liquidity passagebio.com
- net income and valuation ratios data:
PASG - Company Net Income|Forward Earnings Passage Bio, Inc.|PASG - P/E Multiple|Forward P/E Multiple passagebio.com|PASG - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Passage Bio Corp|PASG - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Passage Bio|PASG - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth passagebio.com|PASG - Earnings growth in current year|Net earnings per one share growth forecast for next year Passage Bio, Inc.
Summary company analytics:PASG Passage Bio Inc.
Professional asset selection requires comparing current quotes with the average valuation of independent experts to determine the fair value of the business. This consensus-based projected share price aggregates market expectations for the capitalization of Passage Bio, Inc. (PASG), where orphan drug status and a monopoly in CNS therapy create a foundation for high margins, as reflected in the price action of this chart.
Competitors of Passage Bio, Inc.
BIIB: Forecast Levels Chart|Analyst Consensus Forecast NBIX (Neurocrine Biosciences, Inc.)|Analyst Consensus Forecast Regencell Bioscience Ltd RGC|AXSM - Price Target Chart|Analyst Median Target ACADIA Corp ACAD|XENE: Analyst Consensus Forecast|Analyst Target Range vikingtherapeutics.com VKTX|Price Target Chart Supernus|Broker Consensus Forecast CPRX (Catalyst Pharma)|Analyst Consensus Forecast DNLI|HRMY - Average Forecast Price|Biohaven Ltd. - Consensus Target|Analyst Consensus Forecast amylyx.com AMLX|TRVI - Price Target Chart|Fair Value Consensus PRAX (Praxis Precision Medicines Inc)|Anavex Corp (AVXL) - Price Target Chart|Average Forecast Price CeriBell EEG (CBLL)|Price Target Chart Prothena Corporation PLC|Alector Therapeutics - Forecast Levels Chart|Analyst Consensus Forecast ANNX|Analyst Consensus Forecast omeros.com (OMER)|Price Target Chart Neurogene Corp NGNE|Analyst Median Target AC Immune Inc (ACIU)|VYGR - Price Target Chart|Analyst Median Target neumoratx.com NMRA|SCLX: Analyst Consensus Forecast|Tevogen Bio Holdings Inc. (TVGN) - Analyst Consensus Forecast|ACOG (Alpha Cognition Inc) - Analyst Consensus Forecast|CGTX - Analyst Target Range|Analyst Consensus Forecast IKT|SAVA - Average Forecast Price|Assertio - Consensus Target|Fair Value Consensus COYA|VistaGen Therapeutics Inc - Analyst Consensus Forecast|OVID: Price Target Chart|ABOS: Analyst Consensus Forecast|CRVO - Analyst Median Target|Price Target Chart Alterity Therapeutics Ltd.|Average Forecast Price Clene Nanomedicine CLNN|Consensus Target PEPG (PepGen Inc.)|JUNS (jupiterneurosciences.com) - Fair Value Consensus|Analyst Consensus Forecast RLMD (Relmada Therapeutics)|Analyst Median Target annovisbio.com (ANVS)|GRCE - Price Target Chart|AIFF (Firefly Neuroscience, Inc.) - Broker Consensus Forecast|KLTO: Analyst Consensus Forecast|Consensus Target NeuroSense Therapeutics Ltd.|Consensus Target RVPH|MetaVia, Inc. (MTVA) - Analyst Median Target|Price Target Chart NeurAxis (NRXS)|HSDT: Forecast Levels Chart|Analyst Consensus Forecast NEUP (Neuphoria Therapeutics)|Analyst Consensus Forecast Minerva NERV|ATHA - Price Target Chart|Analyst Median Target addextherapeutics.com ADXN|ALZN: Analyst Consensus Forecast|Analyst Target Range Cyclerion Therapeutics, Inc. CYCN|Price Target Chart Protagenic Therapeutics Inc.|Broker Consensus Forecast KTTA (Pasithea)|Analyst Consensus Forecast CRGT|ATXI - Average Forecast Price|BrainStorm Cell Therapeutics - Consensus Target|Analyst Consensus Forecast Cara Therapeutics Inc. CARA|CHRO - Price Target Chart|Fair Value Consensus ELYM (Eliem Therapeutics)|intracellulartherapies.com (ITCI) - Price Target Chart|Average Forecast Price longboardpharma.com (LBPH)|Price Target Chart Marinus Pharmaceuticals, Inc.|NKGen Biotech Inc - Forecast Levels Chart|Analyst Consensus Forecast NRBO|Analyst Consensus Forecast Sage Therapeutics Inc (SAGE)|Price Target Chart Synaptogenix, Inc. SNPX|Analyst Median Target trevena.com (TRVN)|VIGL - Price Target Chart|Analyst Median Target Anew Medical Inc. WENA|CERE: Analyst Consensus Forecast
